ATTEST 2 aims to test tenecteplase in a large clinical trial to establish whether it is a better drug than alteplase for use in thrombolysis. This will involve a large number of hospitals in the UK, and possibly overseas. People who are considered suitable for thrombolysis will be allocated at random to receive either the current standard treatment with alteplase, or tenecteplase, and will be followed up for the first 90 days to measure the effects on recovery.
Even if there are no significant differences between between the two drugs, tenecteplase is less expensive and much easier to give to patients than alteplase, needing a single injection only. Alteplase has to be given as an injection followed by a longer injection over an hour. This advantage of tenecteplase alone would have worthwhile benefits to the patient.
Trial Design
Prospective Randomised Open, Blinded End-point (PROBE) – Phase III
Principal Investigator
Dr. Will Whitely, Stroke Medicine, University of Edinburgh & NHS Lothian
Scottish Senior Clinical Fellow and Consultant Neurologist
Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine
Lead Research Nurse
Stroke Lead Research Nurse
Senior Research Nurse
AMU Senior Research Nurse
Senior Research Nurse
Senior Research Nurse
Senior Stroke Research Nurse
Senior Research Nurse - Stroke/Neurosurgery
Senior Research Nurse - Stroke/Neurosurgery
Senior Research Nurse
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions
Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)
Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.
Identification of Novel Psychoactive Substances (IONA)